Frontier signal stream

On 22 July 2026 Science Corporation announced the European commercial launch of PRIMA, stating it is the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy caused by age-related macular degeneration. PRIMA received a CE mark under the EU Medical Device Regulation from notified body DEKRA, authorising commercial availability across 30 European countries, and the company states it is the first brain-computer-interface device to receive CE marking for form vision restoration - reading letters, numbers and words. Country-specific reimbursement applications and clinical site activations are described as underway, with the first commercial implant expected in Germany. The company cites its New England Journal of Medicine publication covering 38 patients across 17 clinical sites in five countries: mean improvement of 25.5 letters on the ETDRS chart, 84% of patients reporting the ability to read letters, numbers and words, and 80% achieving prosthetic visual acuity improvement of at least logMAR 0.2 at 12 months (p<0.001). The implant is a 2x2mm subretinal photovoltaic device paired with near-infrared projecting glasses. AMD-associated geographic atrophy is stated to affect more than five million people globally.

Precision Neuroscience announced it won a 2026 Webby Award and was named to Fast Company's World Changing Ideas list for a second consecutive year, both citing its Layer 7 cortical interface and its potential to restore communication for people living with paralysis. The release states Precision has implanted the device in more than 90 patients across multiple health systems — the substantive datapoint in the announcement, and an increase on the 'more than 80' figure stated in its 30 April release. No funding figures were stated. NOT flagged as a big event: this is third-party recognition with no disclosed economics and no clinical or commercial milestone. Recorded on the same basis as Island's CNBC Disruptor 50 placement (run 48) and Chainguard's Gartner Magic Quadrant placement (run 35) — logged as recognition, explicitly not as a valuation or performance event.

Emotiv made its Emotiv Play catalogue of brain-controlled games available on its Epoc X and Insight headsets, having previously limited them to the MN8 earbuds. The move broadens the addressable install base for its consumer software across its full wireless EEG hardware line.

Neurable announced a licensing platform allowing OEMs to integrate its AI-powered EEG brain-sensing technology directly into existing hardware such as headphones, hats, glasses and headbands, while retaining full control over product design, user experience and distribution. It marks a shift from bespoke single-partner deals to a scalable platform model, following a $35m Series A in December 2025.

Science Corporation announced the European commercial launch of PRIMA, a treatment to restore functional central vision in patients with geographic atrophy from age-related macular degeneration.